Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mural Oncology (Nasdaq: MURA) has granted equity incentives to five new employees as inducement awards. The grants include 23,500 stock options with an exercise price of $3.46 per share and 12,500 restricted stock units. The stock options have a ten-year term and vest over four years, with 25% vesting after one year and 6.25% quarterly thereafter. The restricted stock units vest 25% annually over four years. These grants were made under the company's 2024 Inducement Stock Option and Incentive Plan in accordance with Nasdaq Rule 5635(c)(4).
Mural Oncology (Nasdaq: MURA) ha concesso incentivi azionari a cinque nuovi dipendenti come premi di indennizzo. Le concessioni includono 23.500 opzioni azionarie con un prezzo di esercizio di $3,46 per azione e 12.500 unità azionarie vincolate. Le opzioni azionarie hanno una durata di dieci anni e maturano in quattro anni, con il 25% che matura dopo un anno e il 6,25% trimestralmente da allora. Le unità azionarie vincolate maturano il 25% annualmente per quattro anni. Queste concessioni sono state effettuate ai sensi del 2024 Inducement Stock Option and Incentive Plan dell'azienda, in conformità con la Regola 5635(c)(4) di Nasdaq.
Mural Oncology (Nasdaq: MURA) ha otorgado incentivos de capital a cinco nuevos empleados como premios de inducimiento. Las concesiones incluyen 23,500 opciones sobre acciones con un precio de ejercicio de $3.46 por acción y 12,500 unidades de acciones restringidas. Las opciones sobre acciones tienen un plazo de diez años y se adquieren en un periodo de cuatro años, con un 25% que se adquiere después de un año y un 6.25% trimestralmente a partir de entonces. Las unidades de acciones restringidas se adquieren al 25% anualmente durante cuatro años. Estas concesiones se realizaron bajo el 2024 Inducement Stock Option and Incentive Plan de la compañía, de acuerdo con la Regla 5635(c)(4) de Nasdaq.
뮤랄 온콜로지 (Nasdaq: MURA)는 새로운 직원 다섯 명에게 유인 보상으로 주식 인센티브를 부여했습니다. 이번 grant에는 23,500주식 옵션이 포함되어 있으며, 행사가는 주당 $3.46이고 12,500 제한된 주식 단위도 포함됩니다. 주식 옵션은 10년의 기간을 갖고 4년에 걸쳐 분할하여 행사할 수 있으며, 1년 후에 25%가 행사되고 이후 매 분기마다 6.25%가 행사됩니다. 제한된 주식 단위는 4년에 걸쳐 매년 25%가 행사됩니다. 이러한 Grant는 회사의 2024 유인 주식 옵션 및 인센티브 계획에 따라 Nasdaq 규정 5635(c)(4)에 따라 이루어졌습니다.
Mural Oncology (Nasdaq: MURA) a accordé des incitations en actions à cinq nouveaux employés sous forme de récompenses incitatives. Les attributions comprennent 23,500 options d'achat d'actions avec un prix d'exercice de 3,46 $ par action et 12,500 unités d'actions restreintes. Les options d'achat d'actions ont une durée de dix ans et s'acquièrent sur quatre ans, avec 25% d'acquisition après un an et 6,25% trimestriellement par la suite. Les unités d'actions restreintes s'acquièrent à hauteur de 25% annuellement pendant quatre ans. Ces attributions ont été effectuées dans le cadre du 2024 Inducement Stock Option and Incentive Plan de l'entreprise, conformément à la règle Nasdaq 5635(c)(4).
Mural Oncology (Nasdaq: MURA) hat fünf neuen Mitarbeitern als Anreiz Ausgleichsleistungen in Form von Aktienoptionen gewährt. Die Zuwendungen umfassen 23.500 Aktienoptionen mit einem Ausübungspreis von 3,46 $ pro Aktie sowie 12.500 eingeschränkte Aktieneinheiten. Die Aktienoptionen haben eine Laufzeit von zehn Jahren und werden über vier Jahre hinweg fällig, wobei 25% nach einem Jahr und danach vierteljährlich 6,25% fällig werden. Die eingeschränkten Aktieneinheiten werden über einen Zeitraum von vier Jahren zu 25% jährlich fällig. Diese Zuwendungen erfolgten im Rahmen des 2024 Inducement Stock Option and Incentive Plan des Unternehmens, gemäß der Nasdaq-Regel 5635(c)(4).
- Implementation of employee stock incentive program to attract and retain talent
- Potential shareholder dilution from issuance of 36,000 new shares
WALTHAM, Mass and DUBLIN, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today announced that on November 1, the Company granted to five newly hired employees (i) non-statutory stock options to purchase an aggregate of 23,500 ordinary shares of the Company and (ii) restricted stock units with respect to an aggregate of 12,500 ordinary shares of the Company, pursuant to the Company’s 2024 Inducement Stock Option and Incentive Plan, each as an inducement material to the new employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock options have an exercise price of
About Mural Oncology
Mural Oncology is leveraging its novel protein engineering platform to develop cytokine-based immunotherapies for the treatment of cancer. By combining our expertise in cytokine biology and immune cell modulation and our protein engineering platform, we are developing medicines to deliver meaningful and clinical benefits to people living with cancer. Our mission is to broaden the potential and reach of cytokine-based immunotherapies to improve the lives of patients. Our lead candidate, nemvaleukin, is currently in potentially registrational trials in mucosal melanoma and platinum-resistant ovarian cancer. Mural Oncology has its registered office in Dublin, Ireland, and its primary facilities in Waltham, Mass. For more information, visit Mural Oncology’s website at www.muraloncology.com and follow us on LinkedIn and X.
Contact
Katie Sullivan
katie.sullivan@muraloncology.com
FAQ
What stock options did Mural Oncology (MURA) grant to new employees in November 2024?
What is the vesting schedule for MURA's November 2024 stock options?
How do the restricted stock units (RSUs) vest in Mural Oncology's November 2024 grant?
